We take your personal privacy very seriously and when you visit our website, please agree to all cookies used. Further information on the processing of personal data can be found in thePrivacy Policy

b1_banpc.jpg b1_banph.jpg

About Us

About Full-Life Technologies

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. 

We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development. 


Team
  • Leadership Team

  • b1_img1.jpg
    Lanny Sun
    Co-founder, Chairman & Chief Executive Officer
  • b1_img2.jpg
    Hong-hoi Ting, D.Phil.
    Co-founder, Board Member & Chief Strategy Officer
  • b1_img3.jpg
    Ravi Chari, Ph.D.
    Chief Scientific Officer
  • b1_img4.jpg
    Nicholas Wong, Ph.D.
    Co-founder & Chief Operating Officer
  • b1_img5.jpg
    Philippe van Put
    General Manager, Europe
  • b1_img6.jpg
    Julie Wu
    Chief Financial Officer
  • b1_img7.png
    James McCarter, Ph.D.
    Vice President & Head of Radioisotope Technology Research
Milestones
  • 2021. 8
    Full-Life Technologies was Founded.

    2021. 8

  • 2021. 12
    Full-Life Technologies completed $10 million in seed round financing.

    2021. 12

  • 2022. 1
    Full-Life Technologies announced four key appointments to its executive team.

    2022. 1

  • 2022. 5
    Full-Life Technologies completed $37 million in series A round financing.

    2022. 5

  • 2022. 8
    Full-Life Technologies Announces Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board

    2022. 8

  • 2022.11
    Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

    2022.11